Header Logo

CLIONA ROONEY

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
Address1102 BATES
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentCenter for Cell & Gene Therapy
    DivisionCenter for Cell & Gene Therapy

    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Molecular Virology & Microbiology
    DivisionMolecular Virology & Microbiology

    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Pathology & Immunology
    DivisionImmunology


    Collapse Research 
    Collapse research activities and funding
    T32GM136554     (VAN DEN VEYVER, IGNATIA B)Jul 1, 2020 - Jun 30, 2025
    NIH
    The Clinical Translational Research Certificate of Added Qualification Program
    Role: Co-Principal Investigator
    T32GM088129     (VAN DEN VEYVER, IGNATIA B)Jul 1, 2010 - Jun 30, 2020
    NIH
    Training Program in Translational Biology and Molecular Medicine
    Role: Co-Principal Investigator
    P01CA094237     (HESLOP, HELEN E)Dec 1, 2001 - Jan 31, 2020
    NIH
    ENHANCING T CELL THERAPY OF CANCER
    Role: Co-Principal Investigator
    S10RR013919     (ROONEY, CLIONA M)Jun 1, 1999 - May 31, 2000
    NIH
    ABI PRISM 7700 SEQUENCE DETECTION SYSTEM
    Role: Principal Investigator
    R01CA074126     (ROONEY, CLIONA M)Apr 1, 1997 - Jan 31, 2002
    NIH
    TREATMENT OF HODGKIN DISEASE WITH GENE MARKED CTL
    Role: Principal Investigator
    R01CA061384     (ROONEY, CLIONA M)Sep 1, 1993 - Jan 31, 2004
    NIH
    CYTOTOXIC T CELL TRANSFER FOR THERAPY OF EBV LYMPHOMA
    Role: Principal Investigator
    U01CA061384     (ROONEY, CLIONA M)Sep 1, 1993 - Dec 31, 1997
    NIH
    CYTOTOXIC T-CELL TRANSFER FOR THERAPY OF EBV-LYMPHOMA
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sarathkumara YD, Van Bibber NW, Liu Z, Heslop HE, Rouce RH, Coghill AE, Rooney CM, Proietti C, Doolan DL. Differential EBV protein-specific antibody response between responders and non-responders to EBVSTs immunotherapy. bioRxiv. 2024 Aug 16. PMID: 39211169; PMCID: PMC11361067.
      Citations:    
    2. Sharma S, Mehta NU, Sauer T, Rollins LA, Dittmer DP, Rooney CM. Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma. Blood Adv. 2024 07 09; 8(13):3360-3371. PMID: 38640255; PMCID: PMC11255116.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    3. Kua L, Ng CH, Tan JW, Tan HC, Seh CC, Wong F, Ong R, Rooney CM, Tan J, Chen Q, Horak ID, Tan KW, Low L. Novel OX40 and 4-1BB derived spacers enhance CD30 CAR activity and safety in CD30 positive lymphoma models. Mol Ther. 2024 Oct 02; 32(10):3504-3521. PMID: 38946142; PMCID: PMC11489532.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    4. Lin FY, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, Mehta B, Lapteva N, Mei Z, Major A, Thakkar S, Shum T, Parikh K, Wu MF, Lindsay HB, Scherer L, Shekar M, Baxter P, Wang T, Grilley B, Moeller K, Hicks J, Roy A, Anastas J, Malbari F, Aldave G, Chintagumpala M, Blaney S, Parsons DW, Brenner MK, Heslop HE, Rooney CM, Omer B. Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 Aug 10; 42(23):2769-2779. PMID: 38771986; PMCID: PMC11305939.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    5. Quach DH, Ganesh HR, Briones YD, Nouraee N, Ma A, Hadidi YF, Sharma S, Rooney CM. Rejection resistant CD30.CAR-modified Epstein-Barr virus-specific T?cells as an off-the-shelf platform for CD30+ lymphoma. Mol Ther Oncol. 2024 Jun 20; 32(2):200814. PMID: 38966037; PMCID: PMC11223124.
      Citations: 2     
    6. Che-Hsing L, Sharma S, Heczey AA, Steffin DHM, Louis CU, Grilley BJ, Thakkar SG, Wu M, Wang T, Rooney CM, Brenner MK, Heslop HE. Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for Neuroblastoma. Res Sq. 2024 Apr 11. PMID: 38659815; PMCID: PMC11042400.
      Citations:    
    7. Shafer P, Leung WK, Woods M, Choi JM, Rodriguez-Plata CM, Maknojia A, Mosquera A, Somes LK, Joubert J, Manliguez A, Ranjan R, Burt B, Lee HS, Zhang B, Fuqua S, Rooney C, Leen AM, Hoyos V. Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing. Cytotherapy. 2024 03; 26(3):266-275. PMID: 38231165; PMCID: PMC10922969.
      Citations:    Fields:    Translation:Humans
    8. Sharma S, Sauer T, Omer BA, Shum T, Rollins LA, Rooney CM. Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein-Barr Virus-Specific T-Cells. Int J Mol Sci. 2023 Oct 31; 24(21). PMID: 37958791; PMCID: PMC10649234.
      Citations:    Fields:    Translation:HumansAnimalsCells
    9. Mandal K, Wicaksono G, Yu C, Adams JJ, Hoopmann MR, Temple WC, Izgutdina A, Escobar BP, Gorelik M, Ihling CH, Nix MA, Naik A, Xie WH, H?bner J, Rollins LA, Reid SM, Ramos E, Kasap C, Steri V, Serrano JAC, Salangsang F, Phojanakong P, McMillan M, Gavallos V, Leavitt AD, Logan AC, Rooney CM, Eyquem J, Sinz A, Huang BJ, Stieglitz E, Smith CC, Moritz RL, Sidhu SS, Huang L, Wiita AP. Structural surfaceomics reveals an AML-specific conformation of integrin ?2 as a CAR T cellular therapy target. Nat Cancer. 2023 Nov; 4(11):1592-1609. PMID: 37904046; PMCID: PMC10663162.
      Citations: 1     Fields:    Translation:HumansCells
    10. Vasileiou S, Hill L, Kuvalekar M, Workineh AG, Watanabe A, Velazquez Y, Lulla S, Mooney K, Lapteva N, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Eagar TN, Carrum G, Grimes KA, Leen AM, Lulla P. Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 2023 Jul 01; 108(7):1840-1850. PMID: 36373249; PMCID: PMC10316279.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    11. Vasileiou S, Kuvalekar M, Velazquez Y, Watanabe A, Narula M, Workineh AG, French-Kim M, Chavez AT, Gilmore S, Rooney CM, Leen AM. Longitudinal analysis of the evolution of cellular immunity to SARS-CoV-2 induced by infection and vaccination. Haematologica. 2023 Jul 01; 108(7):1934-1939. PMID: 36373251; PMCID: PMC10316232.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    12. Sharma S, Woods M, Mehta NU, Sauer T, Parikh KS, Schmuck-Henneresse M, Zhang H, Mehta B, Brenner MK, Heslop HE, Rooney CM. Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. J Immunother Cancer. 2023 04; 11(4). PMID: 37072346; PMCID: PMC10124261.
      Citations:    Fields:    Translation:HumansAnimalsCells
    13. Quach DH, Lulla P, Rooney CM. Banking on virus-specific T cells to fulfill the need for?off-the-shelf cell therapies. Blood. 2023 02 23; 141(8):877-885. PMID: 36574622; PMCID: PMC10023738.
      Citations:    Fields:    Translation:HumansCells
    14. Rooney CM, Mitra S. A Practical Guide to 16S rRNA Microbiome Analysis in Musculoskeletal Disorders. Methods Mol Biol. 2023; 2649:85-105. PMID: 37258859.
      Citations:    Fields:    Translation:HumansCells
    15. Hoyos V, Vasileiou S, Kuvalekar M, Watanabe A, Tzannou I, Velazquez Y, French-Kim M, Leung W, Lulla S, Robertson C, Foreman C, Wang T, Bulsara S, Lapteva N, Grilley B, Ellis M, Osborne CK, Coscio A, Nangia J, Heslop HE, Rooney CM, Vera JF, Lulla P, Rimawi M, Leen AM. Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221107113. PMID: 35860837; PMCID: PMC9290161.
      Citations:    
    16. Steffin DHM, Muhsen IN, Hill LC, Ramos CA, Ahmed N, Hegde M, Wang T, Wu M, Gottschalk S, Whittle SB, Lulla PD, Mamonkin M, Omer B, Rouce RH, Heczey A, Metelitsa LS, Grilley BJ, Robertson C, Torrano V, Lapteva N, Gee AP, Rooney CM, Brenner MK, Heslop HE. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24. PMID: 35325065; PMCID: PMC9346960.
      Citations:    Fields:    Translation:HumansCells
    17. Naik S, Vasileiou S, Tzannou I, Kuvalekar M, Watanabe A, Robertson C, Lapteva N, Tao W, Wu M, Grilley B, Carrum G, Kamble RT, Hill L, Krance RA, Martinez C, Tewari P, Omer B, Gottschalk S, Heslop HE, Brenner MK, Rooney CM, Vera JF, Leen AM, Lulla PD. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711. PMID: 35134127; PMCID: PMC9053698.
      Citations: 1     Fields:    Translation:Humans
    18. Omer B, Cardenas MG, Pfeiffer T, Daum R, Huynh M, Sharma S, Nouraee N, Xie C, Tat C, Perconti S, Van Pelt S, Scherer L, DeRenzo C, Shum T, Gottschalk S, Arber C, Rooney CM. A Costimulatory CAR Improves TCR-based Cancer Immunotherapy. Cancer Immunol Res. 2022 04 01; 10(4):512-524. PMID: 35176142; PMCID: PMC8978620.
      Citations:    Fields:    Translation:AnimalsCells
    19. Zhang X, Zhang R, Ren C, Xu Y, Wu S, Meng C, Pataer A, Song X, Zhang J, Yao Y, He H, Chen H, Ma W, Wang J, Meric-Bernstam F, Champlin RE, Heymach JV, Rooney CM, Swisher SG, Vaporciyan AA, Roth JA, You MJ, Wang M, Fang B. Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Adv. 2022 02 08; 6(3):891-901. PMID: 34861697; PMCID: PMC8945299.
      Citations:    Fields:    Translation:HumansAnimalsCells
    20. Sauer T, Parikh K, Sharma S, Omer B, Sedloev D, Chen Q, Angenendt L, Schliemann C, Schmitt M, Gottschalk S, Rooney CM, M?ller-Tidow C. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 2021 07 29; 138(4):318-330. PMID: 34323938; PMCID: PMC8323977.
      Citations: 19     Fields:    Translation:HumansCells
    21. Kim WS, Oki Y, Kim SJ, Yoon SE, Ardeshna KM, Lin Y, Ruan J, Porcu P, Brammer JE, Jacobsen ED, Yoon DH, Suh C, Radford J, Budde LE, Kim JS, Bachy E, Lee HJ, Bollard CM, Jaccard A, Kang HJ, Inman S, Murray M, Combs KE, Lee DY, Advani R, Gunter KC, Rooney CM, Heslop HE, Suarez F. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Ann Hematol. 2021 Oct; 100(10):2529-2539. PMID: 34304287.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    22. El Fiky A, Ibenana L, Anderson R, Hare JM, Khan A, Gee AP, Rooney C, McKenna DH, Gold J, Kelley L, Lundberg MS, Welniak LA, Lindblad R. The National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: Eighteen years of cell therapy. Clin Transl Sci. 2021 11; 14(6):2099-2110. PMID: 34286927; PMCID: PMC8604220.
      Citations: 1     Fields:    
    23. Rooney CM, McIntyre J, Ritchie L, Wilcox MH. Evidence review of physical distancing and partition screens to reduce healthcare acquired SARS-CoV-2. Infect Prev Pract. 2021 Jun; 3(2):100144. PMID: 34316581; PMCID: PMC8081747.
      Citations:    
    24. Vasileiou S, Lulla PD, Tzannou I, Watanabe A, Kuvalekar M, Callejas WL, Bilgi M, Wang T, Wu MJ, Kamble R, Ramos CA, Rouce RH, Zeng Z, Gee AP, Grilley BJ, Vera JF, Bollard CM, Brenner MK, Heslop HE, Rooney CM, Leen AM, Carrum G. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425. PMID: 33507803; PMCID: PMC8274795.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    25. Heslop HE, Sharma S, Rooney CM. Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas. J Clin Oncol. 2021 02 10; 39(5):514-524. PMID: 33434061; PMCID: PMC8462582.
      Citations: 1     Fields:    Translation:HumansCells
    26. Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 11 10; 38(32):3794-3804. PMID: 32701411; PMCID: PMC7655020.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    27. Ando J, Ngo MC, Ando M, Leen A, Rooney CM. Identification of protective T-cell antigens for smallpox vaccines. Cytotherapy. 2020 11; 22(11):642-652. PMID: 32747299; PMCID: PMC7205715.
      Citations: 1     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    28. Packiriswamy N, Upreti D, Zhou Y, Khan R, Miller A, Diaz RM, Rooney CM, Dispenzieri A, Peng KW, Russell SJ. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. Leukemia. 2020 12; 34(12):3310-3322. PMID: 32327728; PMCID: PMC7581629.
      Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
    29. Lapteva N, Gilbert M, Diaconu I, Rollins LA, Al-Sabbagh M, Naik S, Krance RA, Tripic T, Hiregange M, Raghavan D, Dakhova O, Rouce RH, Liu H, Omer B, Savoldo B, Dotti G, Cruz CR, Sharpe K, Gates M, Orozco A, Durett A, Pacheco E, Gee AP, Ramos CA, Heslop HE, Brenner MK, Rooney CM. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350. PMID: 31558475; PMCID: PMC7062259.
      Citations: 13     Fields:    Translation:HumansCells
    30. Quach DH, Becerra-Dominguez L, Rouce RH, Rooney CM. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells. J Transl Med. 2019 07 24; 17(1):240. PMID: 31340822; PMCID: PMC6657103.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    31. Keller MD, Darko S, Lang H, Ransier A, Lazarski CA, Wang Y, Hanley PJ, Davila BJ, Heimall JR, Ambinder RF, Barrett AJ, Rooney CM, Heslop HE, Douek DC, Bollard CM. T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy. Br J Haematol. 2019 10; 187(2):206-218. PMID: 31219185; PMCID: PMC6786907.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    32. Sauer T, Rooney CM. Current challenges for CAR T-cell therapy of acute myeloid leukemia. Transfusion. 2019 04; 59(4):1171-1173. PMID: 30762880.
      Citations: 4     Fields:    Translation:HumansAnimals
    33. Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS, Gottschalk SM, Rooney CM. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunol Res. 2019 03; 7(3):363-375. PMID: 30651290; PMCID: PMC7906796.
      Citations: 83     Fields:    Translation:HumansAnimalsCells
    34. Omer B, Castillo PA, Tashiro H, Shum T, Huynh MTA, Cardenas M, Tanaka M, Lewis A, Sauer T, Parihar R, Lapteva N, Schmueck-Henneresse M, Mukherjee M, Gottschalk S, Rooney CM. Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells. Front Med (Lausanne). 2018; 5:343. PMID: 30619856; PMCID: PMC6297364.
      Citations: 3     
    35. Kalra M, Gerdemann U, Luu JD, Ngo MC, Leen AM, Louis CU, Rooney CM, Gottschalk S. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy. 2019 02; 21(2):212-223. PMID: 30396848; PMCID: PMC6435433.
      Citations: 10     Fields:    Translation:HumansCells
    36. McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, Hoq F, Grilley B, Marcogliese AM, Hanley PJ, Gee AP, Brenner MK, Rooney CM, Heslop HE, Bollard CM. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361. PMID: 30262660; PMCID: PMC6265652.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    37. Sung JA, Patel S, Clohosey ML, Roesch L, Tripic T, Kuruc JD, Archin N, Hanley PJ, Cruz CR, Goonetilleke N, Eron JJ, Rooney CM, Gay CL, Bollard CM, Margolis DM. HIV-Specific, Ex?Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. Mol Ther. 2018 10 03; 26(10):2496-2506. PMID: 30249388; PMCID: PMC6171327.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    38. Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Savoldo B, Dotti G. In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737. PMID: 30309819; PMCID: PMC6277484.
      Citations: 77     Fields:    Translation:HumansCells
    39. Rooney C, Sauer T. Modeling cytokine release syndrome. Nat Med. 2018 06; 24(6):705-706. PMID: 29808004.
      Citations: 7     Fields:    Translation:HumansCells
    40. Shum T, Kruse RL, Rooney CM. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opin Biol Ther. 2018 06; 18(6):653-664. PMID: 29727246; PMCID: PMC6084433.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    41. O'Neil RT, Saha S, Veach RA, Welch RC, Woodard LE, Rooney CM, Wilson MH. Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo. Nat Commun. 2018 04 10; 9(1):1325. PMID: 29636469; PMCID: PMC5893599.
      Citations: 10     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    42. Castillo P, Wright KE, Kontoyiannis DP, Walsh T, Patel S, Chorvinsky E, Bose S, Hazrat Y, Omer B, Albert N, Leen AM, Rooney CM, Bollard CM, Cruz CRY. A New Method for Reactivating and Expanding T Cells Specific for Rhizopus oryzae. Mol Ther Methods Clin Dev. 2018 Jun 15; 9:305-312. PMID: 30038934; PMCID: PMC6054701.
      Citations: 15     
    43. Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139. PMID: 29315015; PMCID: PMC5891126.
      Citations: 75     Fields:    Translation:HumansCells
    44. Morita D, Nishio N, Saito S, Tanaka M, Kawashima N, Okuno Y, Suzuki S, Matsuda K, Maeda Y, Wilson MH, Dotti G, Rooney CM, Takahashi Y, Nakazawa Y. Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Mol Ther Methods Clin Dev. 2018 Mar 16; 8:131-140. PMID: 29687032; PMCID: PMC5907825.
      Citations: 30     
    45. Mukherjee M, Srinivasan M, Krenciute G, Dakhova O, Zheng Y, Rooney CM, Orange JS, Brenner MK, Mamonkin M, Gomes-Silva D, Cabral JMS. Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep. 2017 Oct 03; 21(1):17-26. PMID: 28978471; PMCID: PMC5645034.
      Citations: 92     Fields:    Translation:HumansAnimalsCells
    46. Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou JZ, Farah R, Dorritie KA, Raptis A, Lim SH, Wang H, Lapteva N, Mei Z, Butterfield LH, Rooney CM, Whiteside TL. Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy. 2017 10; 19(10):1225-1232. PMID: 28864289.
      Citations: 66     Fields:    Translation:HumansCellsCTClinical Trials
    47. Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, Yi Z, Sauer T, Liu D, Parihar R, Castillo P, Liu H, Brenner MK, Metelitsa LS, Gottschalk S, Rooney CM. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 2017 11; 7(11):1238-1247. PMID: 28830878; PMCID: PMC5669830.
      Citations: 93     Fields:    Translation:HumansAnimalsCells
    48. Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo B. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471. PMID: 28805662; PMCID: PMC5669573.
      Citations: 140     Fields:    Translation:HumansCellsCTClinical Trials
    49. Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557. PMID: 28783452; PMCID: PMC5662844.
      Citations: 135     Fields:    Translation:HumansCellsCTClinical Trials
    50. Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101. PMID: 28426845; PMCID: PMC5747970.
      Citations: 269     Fields:    Translation:HumansCellsCTClinical Trials
    51. Tashiro H, Sauer T, Shum T, Parikh K, Mamonkin M, Omer B, Rouce RH, Lulla P, Rooney CM, Gottschalk S, Brenner MK. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213. PMID: 28676343; PMCID: PMC5589064.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    52. Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224. PMID: 28602436; PMCID: PMC5589058.
      Citations: 168     Fields:    Translation:HumansCells
    53. Omer B, Shum T, Tashiro H, Mamonkin M, Lapteva N, Sharma S, Rollins L, Dotti G, Rooney CM, Schmueck-Henneresse M, Reinke P, Volk HD. Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells. J Immunol. 2017 07 01; 199(1):348-362. PMID: 28550199; PMCID: PMC5536854.
      Citations: 22     Fields:    Translation:HumansCells
    54. Tanaka M, Tashiro H, Omer B, Lapteva N, Ando J, Ngo M, Mehta B, Dotti G, Kinchington PR, Leen AM, Rossig C, Rooney CM. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. Clin Cancer Res. 2017 Jul 15; 23(14):3499-3509. PMID: 28183713; PMCID: PMC5511585.
      Citations: 28     Fields:    Translation:HumansAnimalsCellsPHPublic HealthCTClinical Trials
    55. Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, Brenner MK, Fisher WE, Leen AM, Vera JF. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258. PMID: 28129119; PMCID: PMC5363304.
      Citations: 112     Fields:    Translation:HumansAnimalsCells
    56. McLaughlin LP, Gottschalk S, Rooney CM, Bollard CM. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas. Methods Mol Biol. 2017; 1532:255-265. PMID: 27873282.
      Citations: 11     Fields:    Translation:HumansCells
    57. Watanabe N, Bajgain P, Sukumaran S, Ansari S, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology. 2016; 5(12):e1253656. PMID: 28180032; PMCID: PMC5214260.
      Citations: 78     Fields:    
    58. Gundry MC, Brunetti L, Lin A, Mayle AE, Kitano A, Hsu JI, Hoegenauer KA, Rooney CM, Goodell MA, Nakada D, Wagner D. Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. Cell Rep. 2016 10 25; 17(5):1453-1461. PMID: 27783956; PMCID: PMC5087995.
      Citations: 114     Fields:    Translation:HumansAnimalsCells
    59. Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G. Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96. PMID: 27270177; PMCID: PMC4922690.
      Citations: 131     Fields:    Translation:HumansCellsCTClinical Trials
    60. Naik S, Nicholas SK, Martinez CA, Leen AM, Hanley PJ, Gottschalk SM, Rooney CM, Hanson IC, Krance RA, Shpall EJ, Cruz CR, Amrolia P, Lucchini G, Bunin N, Heimall J, Klein OR, Gennery AR, Slatter MA, Vickers MA, Orange JS, Heslop HE, Bollard CM, Keller MD. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol. 2016 05; 137(5):1498-1505.e1. PMID: 26920464; PMCID: PMC4860050.
      Citations: 38     Fields:    Translation:HumansCells
    61. Lapteva N, Parihar R, Rollins LA, Gee AP, Rooney CM. Large-Scale Culture and Genetic Modification of Human Natural Killer Cells for Cellular Therapy. Methods Mol Biol. 2016; 1441:195-202. PMID: 27177667.
      Citations: 8     Fields:    Translation:HumansCells
    62. Galvan DL, O'Neil RT, Foster AE, Huye L, Bear A, Rooney CM, Wilson MH. Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model. PLoS One. 2015; 10(10):e0140744. PMID: 26473608; PMCID: PMC4608718.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    63. Manzo T, Heslop HE, Rooney CM. Antigen-specific T cell therapies for cancer. Hum Mol Genet. 2015 Oct 15; 24(R1):R67-73. PMID: 26160910; PMCID: PMC4572005.
      Citations: 17     Fields:    Translation:HumansCells
    64. Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, Durett AG, Dakhova O, Savoldo B, Di Stasi A, Spencer DM, Lin YF, Liu H, Grilley BJ, Gee AP, Rooney CM, Heslop HE, Brenner MK. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13. PMID: 25977584; PMCID: PMC4481597.
      Citations: 97     Fields:    Translation:HumansCellsCTClinical Trials
    65. Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16. PMID: 25940712; PMCID: PMC4473118.
      Citations: 125     Fields:    Translation:HumansAnimalsCells
    66. Hanley PJ, Melenhorst JJ, Nikiforow S, Scheinberg P, Blaney JW, Demmler-Harrison G, Cruz CR, Lam S, Krance RA, Leung KS, Martinez CA, Liu H, Douek DC, Heslop HE, Rooney CM, Shpall EJ, Barrett AJ, Rodgers JR, Bollard CM. CMV-specific T cells generated from na?ve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med. 2015 Apr 29; 7(285):285ra63. PMID: 25925682; PMCID: PMC4479400.
      Citations: 43     Fields:    Translation:HumansCells
    67. Rooney CM, Schmueck-Henneresse M, Sharaf R, Vogt K, Weist BJ, Landwehr-Kenzel S, Fuehrer H, Jurisch A, Babel N, Reinke P, Volk HD. Peripheral blood-derived virus-specific memory stem T cells mature to functional effector memory subsets with self-renewal potency. J Immunol. 2015 Jun 01; 194(11):5559-67. PMID: 25917088.
      Citations: 17     Fields:    Translation:HumansCells
    68. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96. PMID: 25800760; PMCID: PMC4429176.
      Citations: 373     Fields:    Translation:HumansCellsCTClinical Trials
    69. Sun J, Huye LE, Lapteva N, Mamonkin M, Hiregange M, Ballard B, Dakhova O, Raghavan D, Durett AG, Perna SK, Omer B, Rollins LA, Leen AM, Vera JF, Dotti G, Gee AP, Brenner MK, Myers DG, Rooney CM. Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application. J Immunother Cancer. 2015; 3:5. PMID: 25734008; PMCID: PMC4346112.
      Citations: 17     Fields:    
    70. Saha S, Woodard LE, Charron EM, Welch RC, Rooney CM, Wilson MH. Evaluating the potential for undesired genomic effects of the piggyBac transposon system in human cells. Nucleic Acids Res. 2015 Feb 18; 43(3):1770-82. PMID: 25605795; PMCID: PMC4330379.
      Citations: 19     Fields:    Translation:HumansCells
    71. Sung JA, Lam S, Garrido C, Archin N, Rooney CM, Bollard CM, Margolis DM. Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. J Infect Dis. 2015 Jul 15; 212(2):258-63. PMID: 25589335; PMCID: PMC4490234.
      Citations: 53     Fields:    Translation:HumansCells
    72. Gottschalk S, Rooney CM. Adoptive T-Cell Immunotherapy. Curr Top Microbiol Immunol. 2015; 391:427-54. PMID: 26428384; PMCID: PMC4655436.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    73. Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F, Szmania S. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015 Jan; 38(1):24-36. PMID: 25415285; PMCID: PMC4352951.
      Citations: 79     Fields:    Translation:HumansCellsCTClinical Trials
    74. Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM, Towbin AJ, Rooney CM, Pelusio A, Moon A, Hwang TH, Burke JM, Bell JC, Kirn DH, Breitbach CJ. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther. 2015 Mar; 23(3):602-8. PMID: 25531693; PMCID: PMC4351466.
      Citations: 57     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    75. Farzad L, Cerullo V, Yagyu S, Bertin T, Hemminki A, Rooney C, Lee B, Suzuki M. Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy. Mol Ther Oncolytics. 2014; 1:14008. PMID: 27119096; PMCID: PMC4782941.
      Citations: 15     
    76. Lam S, Sung J, Cruz C, Castillo-Caro P, Ngo M, Garrido C, Kuruc J, Archin N, Rooney C, Margolis D, Bollard C. Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy. Mol Ther. 2015 Feb; 23(2):387-95. PMID: 25366030; PMCID: PMC4445615.
      Citations: 28     Fields:    Translation:HumansCells
    77. Lindblad RW, Ibenana L, Wagner JE, McKenna DH, Hei DJ, Hematti P, Couture LA, Silberstein LE, Armant M, Rooney CM, Gee AP, Welniak LA, Heath Mondoro T, Wood DA, Styers D. Cell therapy product administration and safety: data capture and analysis from the Production Assistance for Cellular Therapies (PACT) program. Transfusion. 2015 Mar; 55(3):674-9. PMID: 25315143; PMCID: PMC4357544.
      Citations: 1     Fields:    Translation:Humans
    78. Vera JF, Gerken C, Rooney CM, Miller T, Pfent C, Wang LL, Wilson-Robles HM, Gottschalk S, Mata M. Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells. J Immunother. 2014 Oct; 37(8):407-15. PMID: 25198528; PMCID: PMC4163948.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    79. Melenhorst JJ, Castillo P, Hanley PJ, Keller MD, Krance RA, Margolin J, Leen AM, Heslop HE, Barrett AJ, Rooney CM, Bollard CM. Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. Mol Ther. 2015 Jan; 23(1):179-83. PMID: 25266309; PMCID: PMC4426803.
      Citations: 15     Fields:    Translation:HumansCells
    80. Saito S, Nakazawa Y, Sueki A, Matsuda K, Tanaka M, Yanagisawa R, Maeda Y, Sato Y, Okabe S, Inukai T, Sugita K, Wilson MH, Rooney CM, Koike K. Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Cytotherapy. 2014 Sep; 16(9):1257-69. PMID: 25108652; PMCID: PMC4948190.
      Citations: 25     Fields:    Translation:HumansCells
    81. Bollard CM, Heslop HE, Rooney CM. Reply to S. Yuan et al. J Clin Oncol. 2014 Sep 01; 32(25):2820-1. PMID: 25049328; PMCID: PMC4145187.
      Citations:    Fields:    Translation:HumansCells
    82. Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C, Leung K, Carrum G, Gee AP, Vera JF, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83. PMID: 24964991; PMCID: PMC4181611.
      Citations: 158     Fields:    Translation:HumansCellsCTClinical Trials
    83. Rooney CM. Can Treg elimination enhance NK cell therapy for AML? Blood. 2014 Jun 19; 123(25):3848-9. PMID: 24948620.
      Citations: 3     Fields:    Translation:HumansCells
    84. Bajgain P, Mucharla R, Wilson J, Welch D, Anurathapan U, Liang B, Lu X, Ripple K, Centanni JM, Hall C, Hsu D, Couture LA, Gupta S, Gee AP, Heslop HE, Leen AM, Rooney CM, Vera JF. Optimizing the production of suspension cells using the G-Rex "M" series. Mol Ther Methods Clin Dev. 2014; 1:14015. PMID: 26015959; PMCID: PMC4362380.
      Citations: 29     
    85. Miller JS, Rooney CM, Curtsinger J, McElmurry R, McCullar V, Verneris MR, Lapteva N, McKenna D, Wagner JE, Blazar BR, Tolar J. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in?vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1252-7. PMID: 24816582; PMCID: PMC4099265.
      Citations: 40     Fields:    Translation:HumansAnimalsCells
    86. Ando J, Leen AM, Ennamuri S, Lapteva N, Vera JF, Min-Venditti A, Mims MP, Heslop HE, Bollard CM, Gottschalk S, Rooney CM, Ngo MC. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother. 2014 May; 37(4):193-203. PMID: 24714353; PMCID: PMC4133102.
      Citations: 28     Fields:    Translation:HumansCells
    87. Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, Liu H, Creighton CJ, Gee AP, Heslop HE, Rooney CM, Savoldo B, Dotti G. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014 Jun 12; 123(24):3750-9. PMID: 24782509; PMCID: PMC4055922.
      Citations: 263     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    88. Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS, Durett AG, Wu MF, Liu H, Leen AM, Savoldo B, Lin YF, Grilley BJ, Gee AP, Spencer DM, Rooney CM, Heslop HE, Brenner MK, Dotti G. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905. PMID: 24753538; PMCID: PMC4064331.
      Citations: 86     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    89. Papadopoulou A, Krance RA, Allen CE, Lee D, Rooney CM, Brenner MK, Leen AM, Heslop HE. Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther. 2014 Jun; 22(6):1134-1138. PMID: 24651135; PMCID: PMC4048900.
      Citations: 15     Fields:    Translation:HumansCells
    90. Wood D, Wesselschmidt R, Hematti P, Gee AP, Rooney C, Silberstein L, Armant M, Couture L, Wagner JE, McKenna DH, Hei D, Mondoro TH, Welniak L, Lindblad R. An update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: a decade of cell therapy. Clin Transl Sci. 2014 Apr; 7(2):93-9. PMID: 24655892; PMCID: PMC4006308.
      Citations: 3     Fields:    Translation:Humans
    91. Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R, Anurathapan U, Rendon D, Heslop HE, Rooney CM, Brenner MK, Vera JF. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220. PMID: 24732709; PMCID: PMC4048899.
      Citations: 82     Fields:    Translation:HumansAnimalsCells
    92. Gottschalk S, Rooney CM. Harnessing the immune system to potentiate oncolytics. Mol Ther. 2014 Feb; 22(2):239-240. PMID: 24487560; PMCID: PMC3916053.
      Citations:    Fields:    Translation:HumansCells
    93. Rooney CM, Leen AM, Vera JF, Heslop HE. T lymphocytes targeting native receptors. Immunol Rev. 2014 Jan; 257(1):39-55. PMID: 24329788; PMCID: PMC3869095.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    94. Lapteva N, Szmania SM, van Rhee F, Rooney CM. Clinical grade purification and expansion of natural killer cells. Crit Rev Oncog. 2014; 19(1-2):121-32. PMID: 24941378; PMCID: PMC4095851.
      Citations: 22     Fields:    Translation:HumansCells
    95. Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, Pro B, Liu H, Wu MF, Lee D, Sheehan AM, Zu Y, Gee AP, Brenner MK, Heslop HE, Rooney CM. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808. PMID: 24344220; PMCID: PMC3940538.
      Citations: 208     Fields:    Translation:HumansCellsCTClinical Trials
    96. Anurathapan U, Chan RC, Hindi HF, Mucharla R, Bajgain P, Hayes BC, Fisher WE, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633. PMID: 24213558; PMCID: PMC3945803.
      Citations: 60     Fields:    Translation:HumansAnimalsCells
    97. Cruz CR, Lam S, Hanley PJ, Bear AS, Langston C, Cohen AJ, Liu H, Martinez CA, Krance RA, Heslop HE, Rooney CM, Hanson IC, Bollard CM. Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy. Clin Exp Immunol. 2013 Oct; 174(1):89-96. PMID: 23763437; PMCID: PMC3784216.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    98. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73. PMID: 24030379; PMCID: PMC3811171.
      Citations: 231     Fields:    Translation:HumansCellsCTClinical Trials
    99. Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H, Martinez CA, Kennedy-Nasser A, Leung KS, Gottschalk SM, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21. PMID: 23783429; PMCID: PMC3831033.
      Citations: 97     Fields:    Translation:HumansCellsCTClinical Trials
    100. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, Dey BR, Grilley BJ, Gee AP, Brenner MK, Rooney CM, Heslop HE. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23. PMID: 23610374; PMCID: PMC3695359.
      Citations: 209     Fields:    Translation:HumansCells
    101. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kirn DH. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013 Mar; 19(3):329-36. PMID: 23396206; PMCID: PMC4268543.
      Citations: 349     Fields:    Translation:HumansCellsCTClinical Trials
    102. Sanchez C, Chan R, Bajgain P, Rambally S, Palapattu G, Mims M, Rooney CM, Leen AM, Brenner MK, Vera JF. Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2013 Jun; 16(2):123-31, S1. PMID: 23295316; PMCID: PMC3883310.
      Citations: 20     Fields:    Translation:HumansCells
    103. Nakazawa Y, Saha S, Galvan DL, Huye L, Rollins L, Rooney CM, Wilson MH. Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes. J Immunother. 2013 Jan; 36(1):3-10. PMID: 23211626; PMCID: PMC3521868.
      Citations: 16     Fields:    Translation:HumansCells
    104. Ramos CA, Narala N, Vyas GM, Leen AM, Gerdemann U, Sturgis EM, Anderson ML, Savoldo B, Heslop HE, Brenner MK, Rooney CM. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother. 2013 Jan; 36(1):66-76. PMID: 23211628; PMCID: PMC3521877.
      Citations: 34     Fields:    Translation:HumansCells
    105. Chakraborty R, Mahendravada A, Perna SK, Rooney CM, Heslop HE, Vera JF, Savoldo B, Dotti G. Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica. 2013 Apr; 98(4):533-7. PMID: 23242592; PMCID: PMC3659983.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    106. Suzuki M, Rooney CM. Adenovirus immunity: X marks the spot. Mol Ther. 2012 Dec; 20(12):2197-8. PMID: 23201614; PMCID: PMC3519998.
      Citations: 1     Fields:    Translation:HumansCells
    107. Gerdemann U, Keukens L, Keirnan JM, Katari UL, Nguyen CT, de Pagter AP, Ramos CA, Kennedy-Nasser A, Gottschalk SM, Heslop HE, Brenner MK, Rooney CM, Leen AM. Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood. 2013 Jan 03; 121(1):207-18. PMID: 23152545; PMCID: PMC3709638.
      Citations: 41     Fields:    Translation:HumansCells
    108. Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, Heslop HE, Brenner MK, Rooney CM, Dotti G, Savoldo B. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res. 2013 Jan 01; 19(1):106-17. PMID: 23149818; PMCID: PMC3693218.
      Citations: 40     Fields:    Translation:HumansCells
    109. Rooney C, Leen A. Moving Successful Virus-specific T-cell Therapy for Hematopoietic Stem Cell Recipients to Late Phase Clinical Trials. Mol Ther Nucleic Acids. 2012 Nov 13; 1:e55. PMID: 23629030; PMCID: PMC3511676.
      Citations: 4     
    110. Saha S, Nakazawa Y, Huye LE, Doherty JE, Galvan DL, Rooney CM, Wilson MH. piggyBac transposon system modification of primary human T cells. J Vis Exp. 2012 Nov 05; (69):e4235. PMID: 23149543; PMCID: PMC3514050.
      Citations: 9     Fields:    Translation:HumansCells
    111. Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J, Dandekar V, Mei Z, Jackson K, Vera J, Ando J, Ngo MC, Coustan-Smith E, Campana D, Szmania S, Garg T, Moreno-Bost A, Vanrhee F, Gee AP, Rooney CM. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012 Oct; 14(9):1131-43. PMID: 22900959; PMCID: PMC4787300.
      Citations: 91     Fields:    Translation:HumansCells
    112. Gerdemann U, Keirnan JM, Katari UL, Yanagisawa R, Christin AS, Huye LE, Perna SK, Ennamuri S, Gottschalk S, Brenner MK, Heslop HE, Rooney CM, Leen AM. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012 Aug; 20(8):1622-32. PMID: 22801446; PMCID: PMC3412490.
      Citations: 107     Fields:    Translation:HumansCells
    113. Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012 Sep; 9(9):510-9. PMID: 22801669; PMCID: PMC3743122.
      Citations: 91     Fields:    Translation:HumansCells
    114. Chakraborty R, Rooney C, Dotti G, Savoldo B. Changes in chemokine receptor expression of regulatory T cells after ex vivo culture. J Immunother. 2012 May; 35(4):329-36. PMID: 22495390; PMCID: PMC3650839.
      Citations: 6     Fields:    Translation:HumansCells
    115. White RE, Naresh KN, Meixlsperger S, Pinaud L, Rooney C, Savoldo B, Coutinho R, Gribben J, Ibrahim HA, Bower M, Nourse JP, Gandhi MK, Middeldorp J, Cader FZ, Murray P, Allday MJ, R?mer PC, B?d?r C, M?nz C. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest. 2012 Apr; 122(4):1487-502. PMID: 22406538; PMCID: PMC3314448.
      Citations: 77     Fields:    Translation:HumansAnimalsCells
    116. Bear AS, Morgan RA, Cornetta K, June CH, Binder-Scholl G, Dudley ME, Feldman SA, Rosenberg SA, Shurtleff SA, Rooney CM, Heslop HE, Dotti G. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther. 2012 Feb; 20(2):246-9. PMID: 22297819; PMCID: PMC3277217.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    117. Ghazi A, Ashoori A, Hanley PJ, Brawley VS, Shaffer DR, Kew Y, Powell SZ, Grossman R, Grada Z, Scheurer ME, Hegde M, Leen AM, Bollard CM, Rooney CM, Heslop HE, Gottschalk S, Ahmed N. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012 Feb-Mar; 35(2):159-68. PMID: 22306904; PMCID: PMC3280423.
      Citations: 35     Fields:    Translation:HumansCells
    118. Sili U, Leen AM, Vera JF, Gee AP, Huls H, Heslop HE, Bollard CM, Rooney CM. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy. 2012 Jan; 14(1):7-11. PMID: 22172091; PMCID: PMC3705934.
      Citations: 22     Fields:    Translation:HumansCells
    119. Rooney CM. Adoptive transfer of virus-directed T cells: will this fly for flu? Cytotherapy. 2012 Feb; 14(2):133-4. PMID: 22149160.
      Citations: 1     Fields:    Translation:HumansCells
    120. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 03; 365(18):1673-83. PMID: 22047558; PMCID: PMC3236370.
      Citations: 654     Fields:    Translation:HumansCellsCTClinical Trials
    121. Muralidharan S, Hanley PJ, Liu E, Chakraborty R, Bollard C, Shpall E, Rooney C, Savoldo B, Rodgers J, Dotti G. Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytes. J Immunol. 2011 Nov 15; 187(10):5221-32. PMID: 22013128; PMCID: PMC3208052.
      Citations: 34     Fields:    Translation:HumansCells
    122. Shaffer DR, Sheehan AM, Yi Z, Rodgers CC, Bollard CM, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. Pediatr Blood Cancer. 2012 Oct; 59(4):758-61. PMID: 21994111; PMCID: PMC3258475.
      Citations: 1     Fields:    Translation:HumansCells
    123. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, Liu H, Wu MF, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6. PMID: 21984804; PMCID: PMC3234664.
      Citations: 490     Fields:    Translation:HumansCellsCTClinical Trials
    124. Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A, Gottschalk SM, Savoldo B, Vera JF, Heslop HE, Brenner MK, Bollard CM, Rooney CM, Leen AM. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011 Dec; 19(12):2258-68. PMID: 21915103; PMCID: PMC3242656.
      Citations: 39     Fields:    Translation:HumansCells
    125. Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, Rooney CM, Heslop HE, Bollard CM. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res. 2011 Nov 15; 17(22):7058-66. PMID: 21908573; PMCID: PMC3218253.
      Citations: 33     Fields:    Translation:HumansCells
    126. Huye LE, Nakazawa Y, Patel MP, Yvon E, Sun J, Savoldo B, Wilson MH, Dotti G, Rooney CM. Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Mol Ther. 2011 Dec; 19(12):2239-48. PMID: 21878902; PMCID: PMC3242659.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    127. Nakazawa Y, Huye LE, Salsman VS, Leen AM, Ahmed N, Rollins L, Dotti G, Gottschalk SM, Wilson MH, Rooney CM. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther. 2011 Dec; 19(12):2133-43. PMID: 21772253; PMCID: PMC3242651.
      Citations: 62     Fields:    Translation:HumansAnimalsCells
    128. Kamdar KY, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant. 2011 Jun; 16(3):274-80. PMID: 21467936; PMCID: PMC3167800.
      Citations: 19     Fields:    Translation:Humans
    129. Gerdemann U, Vera JF, Rooney CM, Leen AM. Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant. J Vis Exp. 2011 May 27; (51). PMID: 21654628; PMCID: PMC3197123.
      Citations: 26     Fields:    Translation:HumansCells
    130. Hanley PJ, Shaffer DR, Cruz CR, Ku S, Tzou B, Liu H, Demmler-Harrison G, Heslop HE, Rooney CM, Gottschalk S, Bollard CM. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011 Sep; 13(8):976-86. PMID: 21539497; PMCID: PMC3692015.
      Citations: 24     Fields:    Translation:HumansCells
    131. Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther. 2011 Jun; 19(6):1008-16. PMID: 21505424; PMCID: PMC3129809.
      Citations: 124     Fields:    Translation:Humans
    132. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6. PMID: 21540550; PMCID: PMC3083795.
      Citations: 473     Fields:    Translation:HumansCells
    133. Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, Gottschalk S, Bollard CM, Rao VK, Marques A, Burbelo PD, Turk SP, Fulton R, Wayne AS, Little RF, Cairo MS, El-Mallawany NK, Fowler D, Sportes C, Bishop MR, Wilson W, Straus SE. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 02; 117(22):5835-49. PMID: 21454450; PMCID: PMC3112034.
      Citations: 100     Fields:    Translation:HumansCells
    134. Ngo MC, Rooney CM, Howard JM, Heslop HE. Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet. 2011 Apr 15; 20(R1):R93-9. PMID: 21415041; PMCID: PMC3095061.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    135. Bollard CM, Gottschalk S, Helen Huls M, Leen AM, Gee AP, Rooney CM. Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy. 2011 May; 13(5):518-22. PMID: 21361747; PMCID: PMC3186062.
      Citations: 13     Fields:    Translation:HumansCells
    136. Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S, Mims M, Luciano L, Shafer J, Leen AM, Heslop HE, Rooney CM, Pane F, Brenner MK, Savoldo B. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood. 2011 Mar 24; 117(12):3353-62. PMID: 21278353; PMCID: PMC3069675.
      Citations: 42     Fields:    Translation:HumansCells
    137. Turnis ME, Rooney CM. Enhancement of dendritic cells as vaccines for cancer. Immunotherapy. 2010 Nov; 2(6):847-62. PMID: 21091116; PMCID: PMC3433954.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    138. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, Gee A, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010 Nov-Dec; 33(9):983-90. PMID: 20948438; PMCID: PMC2964409.
      Citations: 86     Fields:    Translation:HumansCellsCTClinical Trials
    139. Song XT, Turnis ME, Zhou X, Zhu W, Hong BX, Rollins L, Rabinovich B, Chen SY, Rooney CM, Gottschalk S. A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol Ther. 2011 Jan; 19(1):211-7. PMID: 20959814; PMCID: PMC3017450.
      Citations: 13     Fields:    Translation:AnimalsCells
    140. Cruz CR, Hanley PJ, Liu H, Torrano V, Lin YF, Arce JA, Gottschalk S, Savoldo B, Dotti G, Louis CU, Leen AM, Gee AP, Rooney CM, Brenner MK, Bollard CM, Heslop HE. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010 Oct; 12(6):743-9. PMID: 20429793; PMCID: PMC2914831.
      Citations: 34     Fields:    Translation:Cells
    141. Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, Foster AE. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010 Oct; 33(8):780-8. PMID: 20842059; PMCID: PMC2998197.
      Citations: 237     Fields:    Translation:HumansAnimalsCells
    142. Sun J, Dotti G, Huye LE, Foster AE, Savoldo B, Gramatges MM, Spencer DM, Rooney CM. T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther. 2010 Nov; 18(11):2006-17. PMID: 20842106; PMCID: PMC2990520.
      Citations: 42     Fields:    Translation:HumansCells
    143. Turnis ME, Song XT, Bear A, Foster AE, Gottschalk S, Brenner MK, Chen SY, Rooney CM. IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J Immunol. 2010 Oct 01; 185(7):4223-32. PMID: 20817880; PMCID: PMC3153346.
      Citations: 18     Fields:    Translation:AnimalsCells
    144. Shaffer DR, Rooney CM, Gottschalk S. Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation. Immunotherapy. 2010 Sep; 2(5):663-71. PMID: 20874650; PMCID: PMC3075565.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    145. Melenhorst JJ, Leen AM, Bollard CM, Price DA, Rooney CM, Brenner MK, Barrett AJ, Heslop HE, Quigley MF. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010 Nov 25; 116(22):4700-2. PMID: 20709906; PMCID: PMC2996125.
      Citations: 76     Fields:    Translation:HumansCells
    146. Ramos CA, Asgari Z, Liu E, Yvon E, Heslop HE, Rooney CM, Brenner MK, Dotti G. An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells. 2010 Jun; 28(6):1107-15. PMID: 20506146; PMCID: PMC3290395.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    147. Stroncek D, Berlyne D, Fox B, Gee A, Heimfeld S, Lindblad R, Loper K, McKenna D, Rooney C, Sabatino M, Wagner E, Whiteside T, Wood D, Heath-Mondoro T. Developments in clinical cell therapy. Cytotherapy. 2010 May; 12(3):425-8. PMID: 20078383; PMCID: PMC2946235.
      Citations: 15     Fields:    Translation:HumansCells
    148. Shafer JA, Cruz CR, Leen AM, Ku S, Lu A, Rousseau A, Heslop HE, Rooney CM, Bollard CM, Foster AE. Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma. 2010 May; 51(5):870-80. PMID: 20367572; PMCID: PMC2991134.
      Citations: 20     Fields:    Translation:HumansCells
    149. Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK, Dotti G. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010 Jun; 24(6):1160-70. PMID: 20428207; PMCID: PMC2888148.
      Citations: 243     Fields:    Translation:HumansAnimalsCells
    150. Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, Wilson J, Dotti G, Heslop HE, Leen AM, Rooney CM. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010 Apr; 33(3):305-15. PMID: 20445351; PMCID: PMC2946348.
      Citations: 76     Fields:    Translation:HumansCells
    151. Leen AM, Tripic T, Rooney CM. Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2010 Mar; 10(3):337-51. PMID: 20132056; PMCID: PMC2818535.
      Citations: 15     Fields:    Translation:HumansCells
    152. Micklethwaite KP, Savoldo B, Hanley PJ, Leen AM, Demmler-Harrison GJ, Cooper LJ, Liu H, Gee AP, Shpall EJ, Rooney CM, Heslop HE, Brenner MK, Bollard CM, Dotti G. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703. PMID: 20110422; PMCID: PMC2852368.
      Citations: 47     Fields:    Translation:HumansCells
    153. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35. PMID: 19880495; PMCID: PMC2817637.
      Citations: 331     Fields:    Translation:HumansCellsCTClinical Trials
    154. Galvan DL, Nakazawa Y, Kaja A, Kettlun C, Cooper LJ, Rooney CM, Wilson MH. Genome-wide mapping of PiggyBac transposon integrations in primary human T cells. J Immunother. 2009 Oct; 32(8):837-44. PMID: 19752750; PMCID: PMC2796288.
      Citations: 58     Fields:    Translation:HumansCells
    155. Nakazawa Y, Huye LE, Dotti G, Foster AE, Vera JF, Manuri PR, June CH, Rooney CM, Wilson MH. Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J Immunother. 2009 Oct; 32(8):826-36. PMID: 19752751; PMCID: PMC2796278.
      Citations: 59     Fields:    Translation:HumansCells
    156. De Angelis B, Dotti G, Quintarelli C, Huye LE, Zhang L, Zhang M, Pane F, Heslop HE, Brenner MK, Rooney CM, Savoldo B. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009 Nov 26; 114(23):4784-91. PMID: 19759356; PMCID: PMC2786289.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    157. Kaka AS, Shaffer DR, Hartmaier R, Hartmeier R, Leen AM, Lu A, Bear A, Rooney CM, Foster AE. Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes. J Immunother. 2009 Sep; 32(7):726-36. PMID: 19561536; PMCID: PMC2790367.
      Citations: 11     Fields:    Translation:HumansCells
    158. Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, Kennedy-Nasser AA, Leung KS, Gee AP, Krance RA, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009 Nov 05; 114(19):4283-92. PMID: 19700662; PMCID: PMC2774556.
      Citations: 143     Fields:    Translation:HumansCellsCTClinical Trials
    159. Gerdemann U, Christin AS, Vera JF, Ramos CA, Fujita Y, Liu H, Dilloo D, Heslop HE, Brenner MK, Rooney CM, Leen AM. Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009 Sep; 17(9):1616-25. PMID: 19584818; PMCID: PMC2835253.
      Citations: 37     Fields:    Translation:HumansCells
    160. Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, Heslop HE, Gottschalk S. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009 Oct; 17(10):1779-87. PMID: 19532139; PMCID: PMC2835000.
      Citations: 93     Fields:    Translation:HumansAnimalsCells
    161. Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, Gee AP, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 Aug 27; 114(9):1958-67. PMID: 19443656; PMCID: PMC2738578.
      Citations: 98     Fields:    Translation:HumansCells
    162. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, Savoldo B. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402. PMID: 19377047; PMCID: PMC2710932.
      Citations: 237     Fields:    Translation:HumansAnimalsCells
    163. Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano Attianese GM, Leen AM, Liu H, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009 May; 17(5):880-8. PMID: 19259067; PMCID: PMC2835146.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    164. Reed W, Noga SJ, Gee AP, Rooney CM, Wagner JE, McCullough J, McKenna DH, Whiteside TL, Donnenberg AD, Baker AK, Lindblad RW, Wagner EL, Mondoro TH. Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies. Transfusion. 2009 Apr; 49(4):786-96. PMID: 19170985; PMCID: PMC4165072.
      Citations: 15     Fields:    Translation:Humans
    165. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov; 14(11):1264-70. PMID: 18978797; PMCID: PMC2749734.
      Citations: 579     Fields:    Translation:HumansCells
    166. Foster AE, Kwon S, Ke S, Lu A, Eldin K, Sevick-Muraca E, Rooney CM. In vivo fluorescent optical imaging of cytotoxic T lymphocyte migration using IRDye800CW near-infrared dye. Appl Opt. 2008 Nov 01; 47(31):5944-52. PMID: 19122737; PMCID: PMC2744150.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    167. Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12; 113(11):2442-50. PMID: 18971421; PMCID: PMC2656271.
      Citations: 58     Fields:    Translation:HumansCellsCTClinical Trials
    168. Fujita Y, Leen AM, Sun J, Nakazawa Y, Yvon E, Heslop HE, Brenner MK, Rooney CM. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008 Sep; 31(7):665-74. PMID: 18600178; PMCID: PMC2643068.
      Citations: 11     Fields:    Translation:HumansCells
    169. Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, Heslop HE, Rooney CM, Pane F, Savoldo B. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood. 2008 Sep 01; 112(5):1876-85. PMID: 18591381; PMCID: PMC3401035.
      Citations: 50     Fields:    Translation:HumansCells
    170. Foster AE, Dotti G, Lu A, Khalil M, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008 Jun; 31(5):500-5. PMID: 18463534; PMCID: PMC2745436.
      Citations: 117     Fields:    Translation:HumansAnimalsCells
    171. Kaka AS, Foster AE, Weiss HL, Rooney CM, Leen AM. Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale. J Immunother. 2008 May; 31(4):359-69. PMID: 18391760; PMCID: PMC2744357.
      Citations: 21     Fields:    Translation:HumansCells
    172. de Witte MA, Jorritsma A, Swart E, Straathof KC, de Punder K, Haanen JB, Rooney CM, Schumacher TN. An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J Immunol. 2008 May 01; 180(9):6365-73. PMID: 18424760.
      Citations: 12     Fields:    Translation:AnimalsCells
    173. Fujita Y, Rooney CM, Heslop HE. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant. 2008 Jan; 41(2):193-8. PMID: 17982497.
      Citations: 30     Fields:    Translation:HumansCells
    174. Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2008 Jan; 82(1):546-54. PMID: 17942545; PMCID: PMC2224388.
      Citations: 71     Fields:    Translation:HumansCells
    175. Altvater B, Pscherer S, Eing BR, Kuehn J, Rooney CM, Juergens H, Rossig C, Landmeier S. Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function. Cancer Res. 2007 Sep 01; 67(17):8335-43. PMID: 17804749.
      Citations: 14     Fields:    Translation:HumansCells
    176. Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802. PMID: 17638856; PMCID: PMC2018664.
      Citations: 92     Fields:    Translation:HumansAnimalsCells
    177. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, Gee AP, Brenner MK, Rooney CM, Heslop HE. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45. PMID: 17609424; PMCID: PMC2018666.
      Citations: 157     Fields:    Translation:HumansCellsCTClinical Trials
    178. Kaka AS, Rooney CM, Savoldo B. What influence has B-cell depletion on viral infections? Leuk Lymphoma. 2007 Jul; 48(7):1257-8. PMID: 17613749.
      Citations: 1     Fields:    Translation:HumansCells
    179. Foster AE, Leen AM, Lee T, Okamura T, Lu A, Vera J, Atkinson R, Bollard CM, Dotti G, Rooney CM. Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. J Immunother. 2007 Jul-Aug; 30(5):506-16. PMID: 17589291.
      Citations: 14     Fields:    Translation:HumansCells
    180. Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, Bhattacharjee MB, Gilbertson RJ, Shine HD, Weiss HL, Rooney CM, Heslop HE, Gottschalk S. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007 Jun 15; 67(12):5957-64. PMID: 17575166.
      Citations: 85     Fields:    Translation:HumansAnimalsCells
    181. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007 Aug; 13(8):913-24. PMID: 17640595; PMCID: PMC2040267.
      Citations: 104     Fields:    Translation:HumansCells
    182. Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, Zhang L, Heslop HE, Brenner MK, Dotti G. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007 Oct 01; 110(7):2620-30. PMID: 17507664; PMCID: PMC1988944.
      Citations: 114     Fields:    Translation:HumansAnimalsCells
    183. Myers GD, Bollard CM, Wu MF, Weiss H, Rooney CM, Heslop HE, Leen AM. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):677-86. PMID: 17417664.
      Citations: 16     Fields:    Translation:HumansCells
    184. Seiler MP, Gottschalk S, Cerullo V, Ratnayake M, Mane VP, Clarke C, Palmer DJ, Ng P, Rooney CM, Lee B. Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates. Mol Ther. 2007 Feb; 15(2):386-92. PMID: 17235318.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    185. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol. 2007; 25:243-65. PMID: 17129181.
      Citations: 107     Fields:    Translation:HumansAnimalsCells
    186. Leen A, Ratnayake M, Foster A, Heym K, Ahmed N, Rooney CM, Gottschalk S. Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells. J Immunother. 2007 Jan; 30(1):96-107. PMID: 17198088.
      Citations: 15     Fields:    Translation:HumansCells
    187. Lee TC, Goss JA, Rooney CM, Heslop HE, Barshes NR, Caldwell YM, Gee AP, Scott JD, Savoldo B. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant. 2006 Nov-Dec; 20(6):689-94. PMID: 17100717.
      Citations: 9     Fields:    Translation:HumansCells
    188. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6. PMID: 16998485.
      Citations: 254     Fields:    Translation:HumansCells
    189. Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C, Wu J, Heslop HE, Rooney CM, Brenner MK, Dotti G. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006 Dec 01; 108(12):3890-7. PMID: 16926291; PMCID: PMC1895462.
      Citations: 152     Fields:    Translation:HumansAnimalsCells
    190. Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, Lin YF, Quiros-Tejeira RE, Reinke P, Schubert S, Gottschalk S, Finegold MJ, Brenner MK, Rooney CM, Heslop HE. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006 Nov 01; 108(9):2942-9. PMID: 16835376; PMCID: PMC1895521.
      Citations: 84     Fields:    Translation:HumansCells
    191. Kennedy-Nasser AA, Bollard CM, Rooney CM. Adoptive immunotherapy for Hodgkin's lymphoma. Int J Hematol. 2006 Jun; 83(5):385-90. PMID: 16787867.
      Citations: 3     Fields:    Translation:HumansCells
    192. Barshes NR, Lee TR, Goss JA, Goodpastor SE, Huls MH, Rooney CM, Karpen SJ, Wyllie S. Slc11a1 (formerly Nramp1) polymorphisms and susceptibility to post-transplant lymphoproliferative disease following pediatric liver transplantation. Transpl Infect Dis. 2006 Jun; 8(2):108-12. PMID: 16734634.
      Citations:    Fields:    Translation:Humans
    193. Lacuesta K, Buza E, Hauser H, Granville L, Pule M, Corboy G, Finegold M, Weiss H, Chen SY, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother. 2006 May-Jun; 29(3):250-60. PMID: 16699368.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    194. Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant. 2006 May-Jun; 20(3):389-93. PMID: 16824159.
      Citations: 16     Fields:    Translation:HumansCells
    195. Bollard CM, Gottschalk S, Huls MH, Molldrem J, Przepiorka D, Rooney CM, Heslop HE. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May; 47(5):837-42. PMID: 16753867.
      Citations: 11     Fields:    Translation:HumansCells
    196. Leen AM, Bollard CM, Myers GD, Rooney CM. Adenoviral infections in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006 Mar; 12(3):243-51. PMID: 16503493.
      Citations: 14     Fields:    Translation:HumansCells
    197. Foster AE, Rooney CM. Improving T cell therapy for cancer. Expert Opin Biol Ther. 2006 Mar; 6(3):215-29. PMID: 16503732.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    198. Pscherer S, Altvater B, Pule M, Rooney CM, Brenner MK, Vormoor J, Rossig C, B?r A, J?rgens H. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. J Immunother. 2006 Jan-Feb; 29(1):21-31. PMID: 16365597.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    199. Bollard CM, Huls MH, Buza E, Weiss H, Torrano V, Gresik MV, Chang J, Gee A, Gottschalk SM, Carrum G, Brenner MK, Rooney CM, Heslop HE. Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma. 2006 Jan; 6(4):342-7. PMID: 16507214.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    200. Gottschalk S, Bollard CM, Straathof KC, Louis CU, Savoldo B, Dotti G, Brenner MK, Heslop HE, Rooney CM. T cell therapies. Ernst Schering Found Symp Proc. 2006; (4):69-82. PMID: 17824182.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    201. Leen AM, Myers GD, Bollard CM, Huls MH, Sili U, Gee AP, Heslop HE, Rooney CM. T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. Ann N Y Acad Sci. 2005 Dec; 1062:104-15. PMID: 16461793.
      Citations: 12     Fields:    Translation:HumansCells
    202. Rooney CM. Hitchhiker's guide to the T cell. Nat Med. 2005 Oct; 11(10):1051-2. PMID: 16211037.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    203. Straathof KC, Leen AM, Buza EL, Taylor G, Huls MH, Heslop HE, Rooney CM, Bollard CM. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol. 2005 Sep 15; 175(6):4137-47. PMID: 16148164.
      Citations: 33     Fields:    Translation:HumansCells
    204. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Barshes NR, Scott JD, Bristow LJ, O'Mahony CA, Goss JA. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005 Sep; 5(9):2222-8. PMID: 16095501.
      Citations: 42     Fields:    Translation:HumansCells
    205. Meyer S, Brestrich G, Moosmann A, Kern F, Tesfa L, Babel N, Mittenzweig A, Rooney CM, Hammerschmidt W, Volk HD, Reinke P, Hammer MH. HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy. Eur J Immunol. 2005 Jul; 35(7):2250-8. PMID: 15915543.
      Citations: 9     Fields:    Translation:HumansCells
    206. Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK, Pul? MA. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005 Nov; 12(5):933-41. PMID: 15979412.
      Citations: 223     Fields:    Translation:HumansCells
    207. Savoldo B, Rooney CM, Quiros-Tejeira RE, Caldwell Y, Wagner HJ, Lee T, Finegold MJ, Dotti G, Heslop HE, Goss JA. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant. 2005 Mar; 5(3):566-72. PMID: 15707412.
      Citations: 26     Fields:    Translation:HumansCells
    208. Straathof KC, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM, Rooney CM, Pul? MA. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005 Jun 01; 105(11):4247-54. PMID: 15728125; PMCID: PMC1895037.
      Citations: 297     Fields:    Translation:HumansAnimalsCells
    209. Dotti G, Savoldo B, Pule M, Straathof KC, Biagi E, Yvon E, Vigouroux S, Brenner MK, Rooney CM. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood. 2005 Jun 15; 105(12):4677-84. PMID: 15713795; PMCID: PMC1895003.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    210. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005; 56:29-44. PMID: 15660500.
      Citations: 132     Fields:    Translation:HumansCells
    211. Leen AM, Rooney CM. Adenovirus as an emerging pathogen in immunocompromised patients. Br J Haematol. 2005 Jan; 128(2):135-44. PMID: 15638847.
      Citations: 35     Fields:    Translation:HumansCells
    212. Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma. 2005 Jan; 46(1):1-10. PMID: 15621775.
      Citations: 43     Fields:    Translation:Humans
    213. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004 Dec 20; 200(12):1623-33. PMID: 15611290; PMCID: PMC2211993.
      Citations: 131     Fields:    Translation:HumansCells
    214. McCullough J, Wagner J, Key N, Gee A, Rooney C, Whiteside T, Donnenberg A, Lindblad R. Production assistance for cellular therapies. Transfusion. 2004 Dec; 44(12):1793-5. PMID: 15584997.
      Citations: 1     Fields:    Translation:Humans
    215. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood. 2005 Mar 01; 105(5):1898-904. PMID: 15542583.
      Citations: 128     Fields:    Translation:HumansCellsCTClinical Trials
    216. Foster AE, Bradstock KF, Sili U, Marangolo M, Rooney CM, Gottlieb DJ. A comparison of gene transfer and antigen-loaded dendritic cells for the generation of CD4+ and CD8+ cytomegalovirus-specific T cells in HLA-A2+ and HLA-A2- donors. Biol Blood Marrow Transplant. 2004 Nov; 10(11):761-71. PMID: 15505607.
      Citations: 6     Fields:    Translation:HumansCells
    217. Pakakasama S, Eames GM, Morriss MC, Huls MH, Rooney CM, Heslop HE, Krance RA. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation. 2004 Sep 15; 78(5):755-7. PMID: 15371682.
      Citations: 10     Fields:    Translation:HumansCells
    218. Heslop HE, Savoldo B, Rooney CM. Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease. Best Pract Res Clin Haematol. 2004 Sep; 17(3):401-13. PMID: 15498712.
      Citations: 5     Fields:    Translation:HumansCells
    219. Leen AM, Sili U, Vanin EF, Jewell AM, Xie W, Vignali D, Piedra PA, Brenner MK, Rooney CM. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood. 2004 Oct 15; 104(8):2432-40. PMID: 15265797.
      Citations: 55     Fields:    Translation:HumansAnimalsCells
    220. Heslop HE, Gottschalk SM, Bollard CM, Straathof KC, Huls MH, Brenner MK, Rooney CM. Options for T-cell based therapies. Vox Sang. 2004 Jul; 87 Suppl 2:230-4. PMID: 15209923.
      Citations:    Fields:    Translation:HumansCells
    221. Bollard CM, Straathof KC, Huls MH, Leen A, Lacuesta K, Davis A, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004 Jul-Aug; 27(4):317-27. PMID: 15235393.
      Citations: 35     Fields:    Translation:HumansCells
    222. Yotnda P, Savoldo B, Charlet-Berguerand N, Rooney C, Brenner M. Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood. 2004 Oct 15; 104(8):2272-80. PMID: 15161664.
      Citations: 15     Fields:    Translation:HumansCells
    223. Bollard CM, Kuehnle I, Leen A, Rooney CM, Heslop HE. Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004 Mar; 10(3):143-55. PMID: 14993880.
      Citations: 32     Fields:    Translation:HumansCells
    224. Voo KS, Fu T, Wang HY, Tellam J, Heslop HE, Brenner MK, Rooney CM, Wang RF. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med. 2004 Feb 16; 199(4):459-70. PMID: 14769850; PMCID: PMC2211826.
      Citations: 62     Fields:    Translation:HumansCells
    225. Wagner HJ, Bollard CM, Huls MH, Anderson R, Prentice HG, Brenner MK, Heslop HE, Rooney CM, Vigouroux S. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther. 2004 Feb; 11(2):81-91. PMID: 14685154.
      Citations: 33     Fields:    Translation:HumansCells
    226. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, Brenner MK, Rooney CM, Heslop HE. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004 May 15; 103(10):3979-81. PMID: 14751931.
      Citations: 48     Fields:    Translation:HumansCells
    227. Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, Huang XF, Chen SY. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res. 2003 Oct 15; 9(13):4743-55. PMID: 14581345.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    228. Leen AM, Sili U, Savoldo B, Jewell AM, Piedra PA, Brenner MK, Rooney CM. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood. 2004 Feb 01; 103(3):1011-9. PMID: 14525768.
      Citations: 38     Fields:    Translation:HumansCells
    229. Yvon E, Wagner HJ, Biagi E, Dotti G, Sili U, Lira C, Rooney CM, Brenner MK, Vigouroux S. Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes. J Virol. 2003 Oct; 77(20):10872-80. PMID: 14512537; PMCID: PMC224961.
      Citations: 35     Fields:    Translation:HumansCells
    230. Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED, Bollard C, Michalek J, Ghetie V, Heslop HE, Molldrem JJ, Rooney CM, Schlinder J, Vitetta E, Brenner MK. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003 Sep 15; 102(6):2292-9. PMID: 12763937.
      Citations: 40     Fields:    Translation:HumansCells
    231. Schroers R, Rooney CM, Gahn B, Chen SY, Kr?ger S. Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J Immunother. 2003 May-Jun; 26(3):212-21. PMID: 12806275.
      Citations: 12     Fields:    Translation:HumansCells
    232. Sili U, Huls MH, Davis AR, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother. 2003 May-Jun; 26(3):241-56. PMID: 12806278.
      Citations: 23     Fields:    Translation:HumansCells
    233. Ling PD, Lednicky JA, Keitel WA, Poston DG, White ZS, Peng R, Liu Z, Mehta SK, Pierson DL, Rooney CM, Vilchez RA, Smith EO, Butel JS. The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis. 2003 May 15; 187(10):1571-80. PMID: 12721937.
      Citations: 61     Fields:    Translation:HumansCells
    234. Straathof KC, Spencer DM, Sutton RE, Rooney CM. Suicide genes as safety switches in T lymphocytes. Cytotherapy. 2003; 5(3):227-30. PMID: 12850790.
      Citations: 10     Fields:    Translation:HumansCells
    235. Huls MH, Rooney CM, Heslop HE. Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease. Acta Haematol. 2003; 110(2-3):149-53. PMID: 14583675.
      Citations:    Fields:    Translation:HumansCells
    236. Wagner HJ, Sili U, Gahn B, Vigouroux S, Huls MH, Xie W, Vignali D, Brenner MK, Heslop HE, Rooney CM. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15. Cytotherapy. 2003; 5(3):231-40. PMID: 12850791.
      Citations: 3     Fields:    Translation:HumansCells
    237. Bollard CM, Savoldo B, Rooney CM, Heslop HE. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol. 2003; 110(2-3):139-48. PMID: 14583674.
      Citations: 11     Fields:    Translation:HumansCells
    238. Straathof KC, Bollard CM, Rooney CM, Heslop HE. Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist. 2003; 8(1):83-98. PMID: 12604735.
      Citations: 7     Fields:    Translation:HumansCells
    239. Voo KS, Fu T, Heslop HE, Brenner MK, Rooney CM, Wang RF. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res. 2002 Dec 15; 62(24):7195-9. PMID: 12499257.
      Citations: 22     Fields:    Translation:HumansCells
    240. Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, Heslop HE, Rooney CM. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003 Mar 01; 101(5):1905-12. PMID: 12411306.
      Citations: 73     Fields:    Translation:HumansCells
    241. Straathof KC, Savoldo B, Heslop HE, Rooney CM. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol. 2002 Sep; 118(3):728-40. PMID: 12181039.
      Citations: 7     Fields:    Translation:Humans
    242. Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, Sabat R, Babel N, Jones JF, Webster-Cyriaque J, Gee AP, Brenner MK, Heslop HE, Rooney CM. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002 Dec 01; 100(12):4059-66. PMID: 12393655.
      Citations: 43     Fields:    Translation:HumansCellsCTClinical Trials
    243. Bollard CM, Calonge MJ, Huls MH, Wagner HJ, Massague J, Brenner MK, Heslop HE, Rooney CM, R?ssig C. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002 May 01; 99(9):3179-87. PMID: 11964281.
      Citations: 167     Fields:    Translation:HumansCells
    244. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002 Mar 15; 99(6):2009-16. PMID: 11877273.
      Citations: 81     Fields:    Translation:HumansCells
    245. Savoldo B, Cubbage ML, Durett AG, Goss J, Huls MH, Liu Z, Teresita L, Gee AP, Ling PD, Brenner MK, Heslop HE, Rooney CM. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002 Jan 15; 168(2):909-18. PMID: 11777989.
      Citations: 30     Fields:    Translation:HumansCells
    246. Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, Brenner MK, Heslop HE, Rooney CM. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res. 2002; 159:123-33. PMID: 11785836.
      Citations: 19     Fields:    Translation:HumansCells
    247. Wagner HJ, Rooney CM, Heslop HE. Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002; 8(1):1-8. PMID: 11846351.
      Citations: 7     Fields:    Translation:Humans
    248. Scherer SP, Baer A, Vormoor J, Rooney CM, Brenner MK, Juergens H, Roessig C. Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Ann Hematol. 2002; 81 Suppl 2:S42-3. PMID: 12611072.
      Citations: 10     Fields:    Translation:HumansCells
    249. Heslop HE, Bollard CM, Gottschalk S, Kuehnle I, Huls MH, Gee AP, Brenner MK, Rooney CM. Immune therapy for EBV infections after hemopoietic stem-cell transplant. Cytotherapy. 2002; 4(5):433-4. PMID: 12473214.
      Citations: 4     Fields:    Translation:HumansCells
    250. Gahn B, Hunt G, Rooney CM, Heslop HE. Immunotherapy to reconstitute immunity to DNA viruses. Semin Hematol. 2002 Jan; 39(1):41-7. PMID: 11799528.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    251. Rooney CM, Bollard C, Huls MH, Gahn B, Gottschalk S, Wagner HJ, Anderson R, Prentice HG, Brenner MK, Heslop HE. Immunotherapy for Hodgkin's disease. Ann Hematol. 2002; 81 Suppl 2:S39-42. PMID: 12611071.
      Citations: 8     Fields:    Translation:HumansCells
    252. Savoldo B, Goss J, Liu Z, Huls MH, Doster S, Gee AP, Brenner MK, Heslop HE, Rooney CM. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation. 2001 Sep 27; 72(6):1078-86. PMID: 11579304.
      Citations: 20     Fields:    Translation:HumansCells
    253. Gahn B, Siller-Lopez F, Pirooz AD, Yvon E, Gottschalk S, Longnecker R, Brenner MK, Heslop HE, Aguilar-Cordova E, Rooney CM. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. Int J Cancer. 2001 Sep 01; 93(5):706-13. PMID: 11477583.
      Citations: 22     Fields:    Translation:HumansCells
    254. Dotti G, Savoldo B, Takahashi S, Goltsova T, Brown M, Rill D, Rooney C, Brenner M. Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy. Exp Hematol. 2001 Aug; 29(8):952-61. PMID: 11495701.
      Citations: 10     Fields:    Translation:HumansCells
    255. Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE, Rooney CM. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001 Feb 15; 97(4):835-43. PMID: 11159505.
      Citations: 98     Fields:    Translation:HumansCells
    256. Hong R, Shen V, Rooney C, Hughes DP, Smith C, Comoli P, Zhang L. Correction of DiGeorge anomaly with EBV-induced lymphoma by transplantation of organ-cultured thymus and Epstein-Barr-specific cytotoxic T lymphocytes. Clin Immunol. 2001 Jan; 98(1):54-61. PMID: 11141327.
      Citations: 6     Fields:    Translation:HumansCells
    257. Rooney CM, Aguilar LK, Huls MH, Brenner MK, Heslop HE. Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol. 2001; 258:221-9. PMID: 11443864.
      Citations: 13     Fields:    Translation:HumansCells
    258. Savoldo B, Heslop HE, Rooney CM. The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients. Leuk Lymphoma. 2000 Nov; 39(5-6):455-64. PMID: 11342329.
      Citations: 2     Fields:    Translation:HumansCells
    259. You Z, Huang XF, Hester J, Rollins L, Rooney C, Chen SY. Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway. J Immunol. 2000 Oct 15; 165(8):4581-91. PMID: 11035100.
      Citations: 10     Fields:    Translation:AnimalsCells
    260. Heslop H, Rooney C, Brenner M, Krance R, Carrum G, Gahn B, Bollard C, Khan S, Gee A, Popat U, Gresik M, Przepiorka D, Kuehnle I, Grilley B. Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 2000 Jul 01; 11(10):1465-75. PMID: 10910143.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    261. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, Rooney CM, Heslop HE. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5. PMID: 10666232.
      Citations: 42     Fields:    Translation:HumansCells
    262. Schroers R, Sinha I, Segall H, Schmidt-Wolf IG, Rooney CM, Brenner MK, Sutton RE, Chen SY. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol Ther. 2000 Feb; 1(2):171-9. PMID: 10933928.
      Citations: 31     Fields:    Translation:HumansCells
    263. Roskrow MA, Dilloo D, Suzuki N, Zhong W, Rooney CM, Brenner MK. Autoimmune disease induced by dendritic cell immunization against leukemia. Leuk Res. 1999 Jun; 23(6):549-57. PMID: 10374848.
      Citations: 14     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    264. Aguilar LK, Rooney CM, Heslop HE. Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Curr Opin Oncol. 1999 Mar; 11(2):96-101. PMID: 10188073.
      Citations: 5     Fields:    Translation:HumansCells
    265. Heslop HE, Perez M, Benaim E, Rochester R, Brenner MK, Rooney CM. Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. J Clin Apher. 1999; 14(3):154-6. PMID: 10540372.
      Citations: 5     Fields:    Translation:HumansCells
    266. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998 Sep 01; 92(5):1549-55. PMID: 9716582.
      Citations: 279     Fields:    Translation:HumansCells
    267. Smith CA, Woodruff LS, Rooney C, Kitchingman GR. Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Hum Gene Ther. 1998 Jul 01; 9(10):1419-27. PMID: 9681413.
      Citations: 29     Fields:    Translation:HumansCells
    268. Kitchingman GR, Rooney C. Cytotoxic T cells and immunotherapy. Pediatr Radiol. 1998 Jul; 28(7):489-91. PMID: 9662564.
      Citations:    Fields:    Translation:HumansCells
    269. Roskrow MA, Rooney CM, Heslop HE, Brenner MK, Krance RA, Gresik MV, McClain K, Aguilar LK, Grilley B, Rob E, Carrum G. Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 1998 May 20; 9(8):1237-50. PMID: 9625264.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    270. Roskrow MA, Suzuki N, Gan Yj, Sixbey JW, Ng CY, Kimbrough S, Hudson M, Brenner MK, Heslop HE, Rooney CM. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998 Apr 15; 91(8):2925-34. PMID: 9531603.
      Citations: 70     Fields:    Translation:HumansCellsCTClinical Trials
    271. Rooney CM, Roskrow MA, Smith CA, Brenner MK, Heslop HE. Immunotherapy for Epstein-Barr virus-associated cancers. J Natl Cancer Inst Monogr. 1998; (23):89-93. PMID: 9709309.
      Citations: 9     Fields:    Translation:HumansCells
    272. Rooney CM, Heslop HE, Brenner MK. EBV specific CTL: a model for immune therapy. Vox Sang. 1998; 74 Suppl 2:497-8. PMID: 9704488.
      Citations: 5     Fields:    Translation:HumansCells
    273. Rooney CM, Roskrow MA, Suzuki N, Ng CY, Brenner MK, Heslop H. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol. 1998; 9 Suppl 5:S129-32. PMID: 9926252.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    274. Brenner MK, Heslop HE, Rooney CM. Gene and cell transfer for specific immunotherapy. Vox Sang. 1998; 74 Suppl 2:87-90. PMID: 9704428.
      Citations:    Fields:    Translation:HumansCells
    275. Tanner JE, Diaz-Mitoma F, Rooney CM, Alfieri C. Anti-interleukin-10 antibodies in patients with chronic active Epstein-Barr virus infection. J Infect Dis. 1997 Dec; 176(6):1454-61. PMID: 9395354.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    276. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev. 1997 Jun; 157:217-22. PMID: 9255632.
      Citations: 39     Fields:    Translation:HumansCells
    277. Rooney CM, Smith CA, Heslop HE. Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity. Mol Med Today. 1997 Jan; 3(1):24-30. PMID: 9021739.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    278. Smith CA, Woodruff LS, Kitchingman GR, Rooney CM. Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro. J Virol. 1996 Oct; 70(10):6733-40. PMID: 8794310; PMCID: PMC190716.
      Citations: 22     Fields:    Translation:HumansCells
    279. Smith CA, Ng CY, Loftin SK, Li C, Heslop HE, Brenner MK, Rooney CM. Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. Leuk Lymphoma. 1996 Oct; 23(3-4):213-20. PMID: 9031101.
      Citations: 5     Fields:    Translation:HumansCells
    280. Brenner MK, Heslop HE, Rill D, Li C, Smith C, Krance R, Rooney C. Transfer of marker genes into hemopoietic progenitor cells. Cytokines Mol Ther. 1996 Sep; 2(3):193-200. PMID: 9384704.
      Citations:    Fields:    Translation:HumansCells
    281. Cohen AR, Rooney C. Osteolysis circumscripta evanescans. Pediatr Neurosurg. 1996 Sep; 25(3):156-8; discussion 158-9. PMID: 9144716.
      Citations:    Fields:    Translation:Humans
    282. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996 May; 2(5):551-5. PMID: 8616714.
      Citations: 198     Fields:    Translation:HumansCells
    283. Cela ME, Holladay MS, Rooney CM, Richardson S, Alexander B, Krance RA, Brenner MK, Heslop HE. Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant. 1996 Feb; 17(2):243-7. PMID: 8640174.
      Citations: 12     Fields:    Translation:HumansCells
    284. Heslop HE, Rooney CM, Rill DR, Krance RA, Brenner MK. Use of gene marking in bone marrow transplantation. Cancer Detect Prev. 1996; 20(2):108-13. PMID: 8706035.
      Citations: 2     Fields:    Translation:HumansCells
    285. Heslop HE, Rooney CM, Brenner MK. Gene-marking and haemopoietic stem-cell transplantation. Blood Rev. 1995 Dec; 9(4):220-5. PMID: 8839397.
      Citations: 1     Fields:    Translation:Humans
    286. Wrightham MN, Stewart JP, Janjua NJ, Pepper SD, Sample C, Rooney CM, Arrand JR. Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1. Virology. 1995 Apr 20; 208(2):521-30. PMID: 7538250.
      Citations: 13     Fields:    Translation:HumansCells
    287. Smith CA, Ng CY, Heslop HE, Holladay MS, Richardson S, Turner EV, Loftin SK, Li C, Brenner MK, Rooney CM. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995 Apr; 4(2):73-9. PMID: 7633844.
      Citations: 42     Fields:    Translation:HumansCells
    288. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995 Jan 07; 345(8941):9-13. PMID: 7799740.
      Citations: 271     Fields:    Translation:HumansCells
    289. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995 Jan; 89(1):98-103. PMID: 7833284.
      Citations: 27     Fields:    Translation:HumansCells
    290. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994 Sep 08; 331(10):679-80. PMID: 8052285.
      Citations: 62     Fields:    Translation:HumansCells
    291. Stewart JP, Behm FG, Arrand JR, Rooney CM. Differential expression of viral and human interleukin-10 (IL-10) by primary B cell tumors and B cell lines. Virology. 1994 May 01; 200(2):724-32. PMID: 8178456.
      Citations: 13     Fields:    Translation:HumansCells
    292. Heslop HE, Li C, Krance RA, Loftin SK, Rooney CM. Epstein-Barr infection after bone marrow transplantation. Blood. 1994 Mar 15; 83(6):1706-8. PMID: 8123864.
      Citations: 3     Fields:    Translation:HumansCells
    293. Heslop HE, Brenner MK, Rooney C, Krance RA, Roberts WM, Rochester R, Smith CA, Turner V, Sixbey J, Moen R, et al. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97. PMID: 8018749.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    294. Brenner MK, Heslop HE, Rill D, Li C, Nilson T, Roberts M, Smith C, Krance R, Rooney C. Gene transfer and bone marrow transplantation. Cold Spring Harb Symp Quant Biol. 1994; 59:691-7. PMID: 7587132.
      Citations: 1     Fields:    Translation:HumansCells
    295. Brenner MK, Rill DR, Heslop HE, Rooney CM, Roberts WM, Li C, Nilson T, Krance RA. Gene marking after bone marrow transplantation. Eur J Cancer. 1994; 30A(8):1171-6. PMID: 7654451.
      Citations: 3     Fields:    Translation:HumansCells
    296. Williams LL, Rooney CM, Conley ME, Brenner MK, Krance RA, Heslop HE. Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet. 1993 Sep 04; 342(8871):587-8. PMID: 8102723.
      Citations: 6     Fields:    Translation:Humans
    297. Stewart JP, Rooney CM. The interleukin-10 homolog encoded by Epstein-Barr virus enhances the reactivation of virus-specific cytotoxic T cell and HLA-unrestricted killer cell responses. Virology. 1992 Dec; 191(2):773-82. PMID: 1333123.
      Citations: 22     Fields:    Translation:HumansCells
    298. Rooney CM, Brimmell M, Buschle M, Allan G, Farrell PJ, Kolman JL. Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes. J Virol. 1992 Jan; 66(1):496-504. PMID: 1309259; PMCID: PMC238310.
      Citations: 31     Fields:    Translation:HumansCells
    299. Rooney CM, Kaye EM, Scott RM, Klucznik RP, Rosman NP. Modified encephaloduroarteriosynangiosis as a surgical treatment of childhood moyamoya disease: report of five cases. J Child Neurol. 1991 Jan; 6(1):24-31. PMID: 2002197.
      Citations: 1     Fields:    Translation:Humans
    300. Buschle M, Brenner MK, Chen IS, Drexler HG, Gignac SM, Rooney CM. Transfection and gene expression in normal and malignant primary B lymphocytes. J Immunol Methods. 1990 Oct 04; 133(1):77-85. PMID: 1698880.
      Citations: 6     Fields:    Translation:HumansCells
    301. Packham G, Economou A, Rooney CM, Rowe DT, Farrell PJ. Structure and function of the Epstein-Barr virus BZLF1 protein. J Virol. 1990 May; 64(5):2110-6. PMID: 2157874; PMCID: PMC249368.
      Citations: 58     Fields:    Translation:AnimalsCells
    302. Rooney CM, Rowe DT, Ragot T, Farrell PJ. The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J Virol. 1989 Jul; 63(7):3109-16. PMID: 2542618; PMCID: PMC250868.
      Citations: 121     Fields:    Translation:HumansCells
    303. Rooney C, Howe JG, Speck SH, Miller G. Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus. J Virol. 1989 Apr; 63(4):1531-9. PMID: 2538644; PMCID: PMC248385.
      Citations: 66     Fields:    Translation:HumansCells
    304. Taylor N, Countryman J, Rooney C, Katz D, Miller G. Expression of the BZLF1 latency-disrupting gene differs in standard and defective Epstein-Barr viruses. J Virol. 1989 Apr; 63(4):1721-8. PMID: 2538652; PMCID: PMC248431.
      Citations: 35     Fields:    Translation:Cells
    305. Farrell PJ, Rowe DT, Rooney CM, Kouzarides T. Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J. 1989 Jan; 8(1):127-32. PMID: 2540954; PMCID: PMC400780.
      Citations: 195     Fields:    Translation:Cells
    306. Rooney C, Taylor N, Countryman J, Jenson H, Kolman J, Miller G. Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency. Proc Natl Acad Sci U S A. 1988 Dec; 85(24):9801-5. PMID: 2849118; PMCID: PMC282869.
      Citations: 52     Fields:    Translation:Cells
    307. Young LS, Yao QY, Rooney CM, Sculley TB, Moss DJ, Rupani H, Laux G, Bornkamm GW, Rickinson AB. New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol. 1987 Nov; 68 ( Pt 11):2853-62. PMID: 2824665.
      Citations: 54     Fields:    Translation:HumansCells
    308. Miller G, Grogan E, Rowe D, Rooney C, Heston L, Eastman R, Andiman W, Niederman J, Lenoir G, Henle W, et al. Selective lack of antibody to a component of EB nuclear antigen in patients with chronic active Epstein-Barr virus infection. J Infect Dis. 1987 Jul; 156(1):26-35. PMID: 3036961.
      Citations: 16     Fields:    Translation:HumansCells
    309. Rooney CM, Edwards CF, Lenoir GM, Rupani H, Rickinson AB. Differential activation of cytotoxic responses by Burkitt's lymphoma (BL)-cell lines: relationship to the BL-cell surface phenotype. Cell Immunol. 1986 Oct 01; 102(1):99-112. PMID: 3026651.
      Citations: 3     Fields:    Translation:HumansCells
    310. Rooney CM, Gregory CD, Rowe M, Finerty S, Edwards C, Rupani H, Rickinson AB. Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines. J Natl Cancer Inst. 1986 Sep; 77(3):681-7. PMID: 2943927.
      Citations: 29     Fields:    Translation:HumansCells
    311. Rowe M, Rooney CM, Edwards CF, Lenoir GM, Rickinson AB. Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma. Int J Cancer. 1986 Mar 15; 37(3):367-73. PMID: 3005176.
      Citations: 29     Fields:    Translation:HumansCells
    312. Rooney CM, Wimperis JZ, Brenner MK, Patterson J, Hoffbrand AV, Prentice HG. Natural killer cell activity following T-cell depleted allogeneic bone marrow transplantation. Br J Haematol. 1986 Mar; 62(3):413-20. PMID: 3513817.
      Citations: 6     Fields:    Translation:HumansCells
    313. Rooney CM, Rowe M, Wallace LE, Rickinson AB. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature. 1985 Oct 17-23; 317(6038):629-31. PMID: 2997615.
      Citations: 37     Fields:    Translation:HumansCells
    314. Rowe M, Rooney CM, Rickinson AB, Lenoir GM, Rupani H, Moss DJ, Stein H, Epstein MA. Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. Int J Cancer. 1985 Apr 15; 35(4):435-41. PMID: 2985508.
      Citations: 32     Fields:    Translation:HumansCells
    315. Rooney CM, Rowe M, Rickinson AB, Lenoir GM, Moss DM, Epstein MA. Endemic and sporadic cases of Epstein-Barr virus-positive Burkitt's lymphoma: immunological characterization of derived cell lines. Haematol Blood Transfus. 1985; 29:308-11. PMID: 2993123.
      Citations:    Fields:    Translation:HumansCells
    316. Rooney CM, Rickinson AB, Moss DJ, Lenoir GM, Epstein MA. Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma. IARC Sci Publ. 1985; (60):249-64. PMID: 2998992.
      Citations: 8     Fields:    Translation:HumansCells
    317. Rooney CM, Rickinson AB, Moss DJ, Lenoir GM, Epstein MA. Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro. Int J Cancer. 1984 Sep 15; 34(3):339-48. PMID: 6090321.
      Citations: 19     Fields:    Translation:HumansCells
    318. Rooney CM, Munro AJ. NK cells can recognize asialylated autologous lymphocytes and ABO-mismatched lymphocytes. Immunology. 1984 Jan; 51(1):193-9. PMID: 6418639; PMCID: PMC1454391.
      Citations: 1     Fields:    Translation:HumansCells
    ROONEY's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (738)
    Explore
    _
    Co-Authors (103)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _